Saturday 17 October 2026
Export LSTA’s income statement to Excel — free account
Lisata Therapeutics, Inc.
LSTA Healthcare Biotechnology
In the quarter to June 2026, revenue fell 98.3%, EPS grew 40.7% and free cash flow grew 33.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.03
0.04
−3.74%
Follow LSTA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | — |
+8 more quarters Free account |
P/S ratio |
— | — | 1.06 | — | |
P/FCF ratio |
— | — | 0.00 | — | |
P/Operating CF |
— | — | (4.97) | — | |
P/B ratio |
— | — | 1.11 | — | |
Price to Tangible BV |
— | — | 1.12 | — | |
EV/Sales |
— | — | 0.22 | — | |
EV/EBITDA |
— | — | 0.00 | — | |
EV/Operating CF |
— | — | (0.21) | — | |
EV/FCF |
— | — | (0.21) | — | |
Quick Ratio |
3.50 | 3.94 | 5.20 | 4.27 | |
Current Ratio |
3.69 | 4.23 | 5.76 | 4.72 | |
Net Debt/EBITDA |
2.62 | 2.64 | 5.21 | 4.33 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.58 | 0.00 | |
Operating CF/Net income |
0.90 | 0.69 | 1.10 | 0.79 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 1,135.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 2,045.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.01 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 225.00% | 0.00% | |
Graham Net Nets |
— | — | 0.90 | — | |
Graham Number |
— | — | 0.00 | — | |
Earnings Yield |
— | — | (102.69%) | — | |
Free Cash Flow Yield |
— | — | (98.88%) | — | |
Revenue per Share |
0.00 | 0.00 | 0.01 | 0.00 | |
Operating CF per Share |
(0.29) | (0.34) | (0.37) | (0.38) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.29) | (0.34) | (0.37) | (0.38) | |
Cash per Share |
1.15 | 1.45 | 1.84 | 2.17 | |
Shareholders Equity per Share |
0.88 | 1.19 | 1.68 | 1.96 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.88 | 1.19 | 1.68 | 1.96 | |
Free Cash Flow |
(2.65) | (3.08) | (3.25) | (3.34) | |
Working Capital |
8.03 | 10.71 | 14.63 | 17.01 | |
Capital Expenditures |
— | — | 0.00 | 0.00 | |
Net Current Asset Value |
7.98 | 10.63 | 14.56 | 16.94 | |
EV/EBIT |
— | — | 0.00 | — | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | — | |
| Other line items | |||||
Average Receivables |
— | — | — | 0.25 | |
Average Payables |
0.81 | 0.56 | 1.15 | 0.59 | |
Average Assets |
18.09 | 21.52 | 26.37 | 29.98 | |
Average Common Equity |
14.38 | 17.89 | 21.96 | 25.28 |
Columns are period end dates